経口固形製剤の受託製造市場：製品、メカニズム、エンドユーザー別-2025-2030年の世界予測

経口固形製剤の受託製造市場は、2023年に408億3,000万米ドルと評価され、2024年には441億6,000万米ドルに達すると予測され、CAGR 8.63%で成長し、2030年には729億1,000万米ドルに達すると予測されています。

経口固形製剤（OSD）受託製造とは、錠剤やカプセルなどの固形製剤の製造を専門の第三者機関に委託することを指します。このアプローチは、製薬会社が生産コストを最適化し、先進技術を利用し、事業を迅速に拡大できるよう支援するものです。その必要性は、医薬品の市場投入までの時間を短縮し、複雑な製剤課題を管理し、厳格な規制要件を遵守するというプレッシャーの高まりから生じています。OSD受託製造は、ジェネリック医薬品の製造、高力価医薬品、新規ドラッグデリバリーシステムなど様々な用途で重要な役割を担っており、最終用途はブランド製薬とバイオテクノロジー企業の両方に及んでいます。主な成長要因としては、ジェネリック医薬品に対する需要の高まり、連続生産などの製造プロセスにおける技術進歩、医薬品消費を押し上げる慢性疾患の有病率の増加などが挙げられます。

新たなビジネスチャンスは、AIやIoTのようなデジタル技術の統合によってもたらされ、効率性とトレーサビリティを向上させています。企業は、スマートな製造方法に投資することで、これを活用することができます。しかし、規制のハードル、品質管理の問題、サプライチェーンの混乱といった制約が大きな課題となっています。技術革新が必要な分野は、より持続可能な製造プロセスの開発であり、環境問題に対処し、世界の持続可能性の動向に合わせることです。もう一つの有望な道は個別化医療であり、受託製造業者はニッチ市場に合わせたソリューションを提供することができます。

市場競争は激化しており、複数の企業が斬新なソリューションを導入するために研究開発に継続的に投資しているため、戦略的パートナーシップは不可欠です。この入り組んだ情勢をうまく乗り切るには、技術の統合、規制の変化、顧客の要望を鋭く理解する必要があります。企業はまた、競争優位性を維持するために、サプライチェーンの回復力を強化し、デジタルトランスフォーメーションを取り入れることに注力すべきです。これらの戦略を活用することで、企業はコンプライアンスと効率性を確保するだけでなく、OSD受託製造市場におけるイノベーションの最前線に立つことができます。

市場力学：急速に進化する経口固形製剤の受託製造市場の主要市場インサイトを公開

経口固形製剤の受託製造市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 製薬企業によるアウトソーシングサービスの採用増加
  • 特許切れとジェネリック医薬品製造の増加
  • 費用対効果の高い医薬品開発プロセスへのニーズ
• 市場抑制要因
  • 経験豊富な技術スタッフの不足
• 市場機会
  • 医薬品開発技術の進歩
  • 経口固形剤（OSD）開発拡大のためのCDMOによる投資の増加
• 市場の課題
  • 規制当局による厳しい承認基準

ポーターの5つの力：経口固形製剤の受託製造市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：経口固形製剤の受託製造市場における外部からの影響の把握

外部マクロ環境要因は、経口固形製剤の受託製造市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析経口固形製剤の受託製造市場における競合情勢の把握

経口固形製剤の受託製造市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス経口固形製剤の受託製造市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、経口固形製剤の受託製造市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨経口固形製剤の受託製造市場における成功への道筋を描く

経口固形製剤の受託製造市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 製薬会社によるアウトソーシングサービスの導入増加
    • 特許切れとジェネリック医薬品製造の増加
    • 費用対効果の高い医薬品開発プロセスの必要性
  • 抑制要因
    • 経験豊富な技術スタッフの不足
  • 機会
    • 医薬品開発技術の進歩の増加
    • 経口固形製剤（OSD）開発拡大に向けたCDMOsによる投資増加
  • 課題
    • 規制当局による厳格な承認基準
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 経口固形製剤の受託製造市場：製品別

• カプセル
• 顆粒
• グミ
• ロゼンジ
• トローチ
• 粉末
• タブレット

第7章 経口固形製剤の受託製造市場：機構別

• 制御放出
• 遅延リリース
• 即時リリース

第8章 経口固形製剤の受託製造市場：エンドユーザー別

• 大企業
• 中堅・中小企業
• スタートアップ企業とジェネリック医薬品企業

第9章 南北アメリカの経口固形製剤の受託製造市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の経口固形製剤の受託製造市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの経口固形製剤の受託製造市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Aenova Holding GmbH
• Alcami Corporation, Inc.
• Aphena Pharma Solutions
• Ardena Holding NV
• Boehringer Ingelheim International GmbH
• Cambrex Corporation
• Corden Pharma International GmbH
• GlaxoSmithKline PLC
• Hermes Pharma GmbH
• Jubilant Pharma Holdings Inc.
• Lonza Group Ltd.
• Novartis AG
• Pfizer Inc.
• Piramal Group
• Recipharm AB

LIST OF FIGURES

• FIGURE 1. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
• FIGURE 2. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET DYNAMICS
• TABLE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GUMMIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY LOZENGES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PASTILLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CONTROLLED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DELAYED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE-RELEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY LARGE-SIZE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MEDIUM- & SMALL-SIZE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STARTUPS & GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. CANADA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. CANADA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 35. CANADA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. CHINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 51. CHINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 52. CHINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. INDIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. INDIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 55. INDIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. ITALY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. ITALY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 107. ITALY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. POLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 118. POLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 119. POLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. QATAR ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. QATAR ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 122. QATAR ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 151. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

The Oral Solid Dosage Contract Manufacturing Market was valued at USD 40.83 billion in 2023, expected to reach USD 44.16 billion in 2024, and is projected to grow at a CAGR of 8.63%, to USD 72.91 billion by 2030.

Oral Solid Dosage (OSD) Contract Manufacturing refers to the outsourcing of the production of solid pharmaceutical forms, such as tablets and capsules, to specialized third-party organizations. This approach supports pharmaceutical companies in optimizing production costs, accessing advanced technologies, and scaling operations rapidly. The necessity arises from the increasing pressure to reduce time-to-market for drugs, manage complex formulation challenges, and comply with stringent regulatory requirements. OSD contract manufacturing is critical in various applications, including generic drug production, high-potency drugs, and novel drug delivery systems, with end-use spanning both branded pharmaceuticals and biotechnology firms. Key growth factors include escalating demand for generics, technological advancements in manufacturing processes such as continuous production, and the increasing prevalence of chronic diseases which boost drug consumption.

Emerging opportunities are being driven by the integration of digital technologies like AI and IoT, improving efficiency and traceability. Companies can capitalize on this by investing in smart manufacturing practices. However, limitations such as regulatory hurdles, quality control issues, and supply chain disruptions pose significant challenges. An area for innovation is the development of more sustainable manufacturing processes, addressing environmental concerns and aligning with global sustainability trends. Another promising avenue is personalized medicine, where contract manufacturers can provide tailored solutions for niche markets.

The market exhibits significant competitive intensity with several players continually investing in R&D to introduce novel solutions, making strategic partnerships vital. Successful navigation of this intricate landscape requires a keen understanding of technology integration, regulatory changes, and customer demands. Businesses should also focus on enhancing supply chain resilience and embracing digital transformation to maintain competitive advantage. By leveraging these strategies, companies not only ensure compliance and efficiency but also position themselves at the forefront of innovation in the OSD contract manufacturing market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oral Solid Dosage Contract Manufacturing Market

The Oral Solid Dosage Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing adoption of outsourcing services by pharmaceutical companies
  • Increasing patent expiration and generic drug manufacturing
  • Need for cost-effective drug development process
• Market Restraints
  • Less availability of experienced technical staff
• Market Opportunities
  • Increase in the advancement of drug development technology
  • Rising investments by CDMOs to expand the oral solid dosage (OSD) development
• Market Challenges
  • Strict approval criteria by regulatory authorities

Porter's Five Forces: A Strategic Tool for Navigating the Oral Solid Dosage Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oral Solid Dosage Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oral Solid Dosage Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oral Solid Dosage Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oral Solid Dosage Contract Manufacturing Market

A detailed market share analysis in the Oral Solid Dosage Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oral Solid Dosage Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oral Solid Dosage Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oral Solid Dosage Contract Manufacturing Market

A strategic analysis of the Oral Solid Dosage Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oral Solid Dosage Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Aenova Holding GmbH, Alcami Corporation, Inc., Aphena Pharma Solutions, Ardena Holding NV, Boehringer Ingelheim International GmbH, Cambrex Corporation, Corden Pharma International GmbH, GlaxoSmithKline PLC, Hermes Pharma GmbH, Jubilant Pharma Holdings Inc., Lonza Group Ltd., Novartis AG, Pfizer Inc., Piramal Group, and Recipharm AB.

Market Segmentation & Coverage

This research report categorizes the Oral Solid Dosage Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Capsules, Granules, Gummies, Lozenges, Pastilles, Powders, and Tablets.
• Based on Mechanism, market is studied across Controlled-Release, Delayed-Release, and Immediate-Release.
• Based on End-User, market is studied across Large-Size Companies, Medium- & Small-Size Companies, and Startups & Generic Pharmaceutical Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing adoption of outsourcing services by pharmaceutical companies
    • 5.1.1.2. Increasing patent expiration and generic drug manufacturing
    • 5.1.1.3. Need for cost-effective drug development process
  • 5.1.2. Restraints
    • 5.1.2.1. Less availability of experienced technical staff
  • 5.1.3. Opportunities
    • 5.1.3.1. Increase in the advancement of drug development technology
    • 5.1.3.2. Rising investments by CDMOs to expand the oral solid dosage (OSD) development
  • 5.1.4. Challenges
    • 5.1.4.1. Strict approval criteria by regulatory authorities
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Oral Solid Dosage Contract Manufacturing Market, by Product

• 6.1. Introduction
• 6.2. Capsules
• 6.3. Granules
• 6.4. Gummies
• 6.5. Lozenges
• 6.6. Pastilles
• 6.7. Powders
• 6.8. Tablets

7. Oral Solid Dosage Contract Manufacturing Market, by Mechanism

• 7.1. Introduction
• 7.2. Controlled-Release
• 7.3. Delayed-Release
• 7.4. Immediate-Release

8. Oral Solid Dosage Contract Manufacturing Market, by End-User

• 8.1. Introduction
• 8.2. Large-Size Companies
• 8.3. Medium- & Small-Size Companies
• 8.4. Startups & Generic Pharmaceutical Companies

9. Americas Oral Solid Dosage Contract Manufacturing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Oral Solid Dosage Contract Manufacturing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Oral Solid Dosage Contract Manufacturing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aenova Holding GmbH
• 2. Alcami Corporation, Inc.
• 3. Aphena Pharma Solutions
• 4. Ardena Holding NV
• 5. Boehringer Ingelheim International GmbH
• 6. Cambrex Corporation
• 7. Corden Pharma International GmbH
• 8. GlaxoSmithKline PLC
• 9. Hermes Pharma GmbH
• 10. Jubilant Pharma Holdings Inc.
• 11. Lonza Group Ltd.
• 12. Novartis AG
• 13. Pfizer Inc.
• 14. Piramal Group
• 15. Recipharm AB